Muñoz, MiguelCrespo, Juan CarlosCrespo, José PedroCoveñas, Rafael2025-01-072025-01-072019-05-102049-9450https://hdl.handle.net/10668/24887Lung cancer (LC) is the leading cause of cancer death and is responsible for more than one-quarter (27%) of all cancer deaths. Non-small-cell LC (NSCLC) is the main histological subtype of LC and is the leading cause of mortalities associated with cancer. This case report focused on a patient showing a history of chronic obstructive pulmonary disease (COPD) with a NSCLC squamous cell carcinoma (single mass with a diameter of 8×7 cm, without metastasis). Due to the COPD, neither a surgical treatment (pneumonectomy) nor chemotherapy was possible. After 15 days following the diagnosis, the patient was treated for 45 days with radiotherapy and the neurokinin-1 receptor, aprepitant (compassionate use, 1,140 mg/day). Radiotherapy was administered to the right lung and mediastinum, reaching 50.4 Gy and then overprinted to 65 Gy. In each successive control, the tumor volume decreased and, after 6 months of treatment, the chest computed tomography scan showed that the tumor mass had disappeared. No side-effects were observed during the combination therapy; in contrast, the patient was in very good general health with a weight gain and showing no biochemical analytical alteration. This case report suggests a witness episode to the antitumor effect of aprepitant/radiotherapy against NSCLC. Urgent development is required for clinical trials to test the combination treatment (radiotherapy and aprepitant) as an antitumor therapy for patients with LC.enEmendPETantitumorchronic obstructive pulmonary diseaseneurokinin-1 receptornon-small cell lung cancernon-small cell lungh cancersubstance Presearch article31289677open access10.3892/mco.2019.1857PMC6543768https://www.spandidos-publications.com/10.3892/mco.2019.1857/downloadhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6543768/pdf